Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

Abstract : Objectives: Evidence comparing the economic and patient values of the World Health Organization's preferred (dolutegravir 50 mg [DTG]-based) and alternative (low-dose [400 mg] efavirenz [EFV400]-based) first-line antiretroviral regimens is limited. We compared patient-reported outcomes (PROs), costs, and the cost-utility of DTG- versus EFV400-based regimens in treatment-naive HIV-1 adults in the randomised NAMSAL ANRS 12313 trial in Yaoundé, Cameroon. Methods: We used clinical data, PROs, and health resource use data collected in the trial’s first 96 weeks (2016–2019). Quality-adjusted life-years (QALYs) were computed using utility scores obtained from the 12-item Short Form (SF-12) generic health scale. Other PROs included perceived symptoms, depression, anxiety, and stress. In the 96-week base-case analysis, we estimated the unadjusted and multivariate-adjusted (1) mean costs (in US$, 2016 values) and QALYs/patient, (2) incremental costs and QALYs/patient, and (3) net health benefit (NHB). Outcomes were extrapolated over 5 and 10 years. Uncertainty was assessed using the cost-effectiveness acceptability curve and scenario and cost-effective price threshold analyses.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-03174666
Contributeur : Anthony Herrada Connectez-vous pour contacter le contributeur
Soumis le : vendredi 19 mars 2021 - 13:54:12
Dernière modification le : vendredi 5 août 2022 - 11:00:18

Fichier

Bousmah2021_Article_Cost-Utili...
Publication financée par une institution

Licence


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License

Identifiants

Collections

Citation

Marwân-Al-Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez, Martial Lantche Wandji, Mireille Mpoudi-Etame, et al.. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). PharmacoEconomics, Springer Verlag, 2021, 39 (3), pp.331-343. ⟨10.1007/s40273-020-00987-3⟩. ⟨hal-03174666⟩

Partager

Métriques

Consultations de la notice

686

Téléchargements de fichiers

144